A brand new weekly injectable drug may rework the lives of greater than eight million folks residing with Parkinson’s illness, doubtlessly changing the necessity for a number of each day tablets.
Scientists from the College of South Australia (UniSA) have developed a long-acting injectable formulation that delivers a gradual dose of levodopa and carbidopa – two key medicines for Parkinson’s – over a whole week.
Their findings have been reported within the journal Drug Supply and Translational Analysis.
The biodegradable formulation is injected underneath the pores and skin or into muscle tissue, the place it progressively releases the medicine over seven days.
Parkinson’s illness is the second commonest neurological dysfunction, affecting greater than 8.5 million folks worldwide. Presently there is no such thing as a remedy and the signs – tremors, rigidity and sluggish motion – are managed with oral medicines that should be taken a number of instances a day.
The frequent dosing is a burden, particularly for aged sufferers or these with swallowing difficulties, resulting in inconsistent medicine ranges, extra uncomfortable side effects, and decreased effectiveness.
Lead researcher Professor Sanjay Garg, from UniSA’s Centre for Pharmaceutical Innovation, says the newly developed injectable may considerably enhance remedy outcomes and affected person adherence.
Our purpose was to create a formulation that simplifies remedy, improves affected person compliance, and maintains constant therapeutic ranges of medicine. This weekly injection may very well be a game-changer for Parkinson’s care.
Levodopa is the gold-standard remedy for Parkinson’s, however its brief life span means it should be taken a number of instances a day.”
Professor Sanjay Garg, from UniSA’s Centre for Pharmaceutical Innovation
UniSA PhD pupil Deepa Nakmode says the in-situ implant is designed to launch each levodopa and carbidopa steadily over one week, sustaining constant plasma ranges and decreasing the dangers related to fluctuating drug concentrations.
The injectable gel combines an FDA-approved biodegradable polymer PLGA with Eudragit L-100, a pH-sensitive polymer, to attain a managed and sustained drug launch.
Intensive lab checks confirmed the system’s effectiveness and security:
- Greater than 90% of the levodopa dose and greater than 81% of the carbidopa dose was launched over seven days.
- The implant degraded by over 80% inside every week and confirmed no vital toxicity in cell viability checks.
- The formulation might be simply administered by a advantageous 22-gauge needle, minimising discomfort and eliminating the necessity for surgical implant.
“The implications of this analysis are profound,” Prof. Garg says. “By decreasing the frequency of dosing from a number of instances a day to a weekly injection is a serious step ahead in Parkinson’s remedy. We’re not simply bettering how the drug is delivered; we’re bettering sufferers’ lives.”
Prof. Garg says the expertise is also tailored for different persistent circumstances akin to most cancers, diabetes, neurodegenerative issues, ache administration, and persistent infections that require long-term drug supply.
The system might be tuned to launch medicine over a interval starting from a couple of days to a number of weeks relying on therapeutic wants.
UniSA scientists hope to start out scientific trials within the close to future and are exploring commercialisation alternatives.
Supply:
Journal reference:
Nakmode, D. D., et al. (2025). Improvement of an in-situ forming implant system for levodopa and carbidopa for the remedy of parkinson’s illness. Drug Supply and Translational Analysis. doi.org/10.1007/s13346-025-01892-y.
